Double-blind RCTs on Magnesium Bisglycinate NMDA/GABA receptor modulation and nocturnal cortisol reduction, antidepressant remission meta-analyses, SAMe augmentation trials, and optical smartwatch HRV validation studies. Explore 674 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Aerobic exercise as well as sertraline reduced symptoms of state anxiety in patients with MDD.
This study did not reveal an association between antidepressants effects of tDCS and baseline rsFC, unlike the gray matter volume findings.
The King's and MiToS staging systems provided utility in assessing clinical progression in Edaravone Study 19.
Galcanezumab reduces the frequency of migraine headache days and can alleviate potentially disabling non-pain symptoms on days when migraine is present in patients with episodic or chronic migraine.
The findings support a growing impression that finasteride is associated with adverse psychiatric effects that can persist in association with sexual dysfunction after discontinuing finasteride treatment.
Our findings indicate that zonisamide improved parkinsonism with DLB without deterioration of cognitive function and or worsening behavioral and psychological symptoms of dementia.
The findings suggest that men with OSA have a high incidence of nocturia.
Despite heterogeneity in exercises, myofunctional therapy decreased AHI by 43% in children, and increased mean oxygen saturations in children with mild to moderate OSA and can serve as an add-on booster OSA treatment.
Enantiomeric bioequivalence explains the previously observed therapeutic equivalence of bupropion generics and brand in treating major depression.
Two investigators independently reviewed the articles and classified the data for meta-analysis.
Finally, there was not any significantly difference between the two study groups in the frequency of side effects.
In contrast, connectivity for remitters was higher than controls at baseline and also following full symptom relief, suggesting a trait-like connectomic characteristic.
OS significantly increased heart and blood vessel risk including the prevalence of high blood pressure and lung high blood pressure.
Eighty-eight participants (age range, 18-85 years) completed a baseline scan; 75 completed a follow-up scan, of which 72 (32 men and 40 women) were useable for final analyses.
Among patients with CKD and MDD, hsCRP correlated with somatic symptoms of depression and fatigue, but not with nonsomatic symptoms.
The results indicate that OSA is one of independent risk factors of PD.
Irrespective of the intervention used, complete resolution of OSA was not achieved in most trials.
This study demonstrated long-term maintenance of efficacy of solriamfetol under open-label and gold-standard blind, compared against a dummy pill (placebo) conditions.
Patient recruitment was a major challenge in this feasibility study.
Conclusions : The association between OSA, anxiety, and depression indicates the value of an early diagnosis and personalized treatment of OSA to improve mental disorders conditioning compliance to therapy.
The overall quality of evidence ranged from low to very low, indicating that caution is required when interpreting these results.
Cortisol concentrations did not differ between adults with OSAS and healthy controls.
Compared with OA, CPAP significantly decreased AHI, min SaO2, ARI, ESS ( p p ≥ 0.05).
We extend existing research by demonstrating that hormone therapy (HT) in subjective sleep cannot be fully explained by improvements in VMS bother or depressive symptoms.
Depression remitted in just over one-half of subjects following sertraline or CBT.
A high degree of suspicion is warranted for OSA in suicidal patients with MDD, and for patients with treatment-resistant depression.
Current treatment options for treatment-resistant depression have considerable limitations in terms of efficacy and patient acceptability.
Telmisartan interacted with rosuvastatin on reducing WMH progression and cognitive function decline.
If replicated, these preliminary findings could help clinicians determine which patients with depression requiring next-step treatment will benefit most from a specific augmentation, combination, or switching strategy.
Limitations include the small number of studies conducted to date.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
